***Welcome to Stillman Translations preliminary onboarding assessment!***

*This assessment has 5 sections. Make sure to follow the instructions and complete all the information needed.*

*The goal of this request is to analyze your performance and your potential.*

*Breathe in and out, and do your best. Hope we can count on you soon!*

**SECTION 1. INSTRUCTIONS**

Below you will find a special instruction for section 3:

\*Please make sure target text mirrors source format.

\*Normalize spaces.

**SECTION 2. GLOSSARY**

*In this section, you are required to complete this task:*

*\*Extract four terms (cells 1 to 4) from the text in Section 3 that you consider are worth being in the glossary.*

|  |  |  |
| --- | --- | --- |
|  | **Source** | **Target** |
| 1 | (DMARD)biologic disease-modifying anti-rheumatic drugs | (FARME) fármacos antirreumáticos modificadores de la enfermedad |
| 2 | Etanercept | El Etanercept |
| 3 | Adalimumab | El Adalimumab |
| 4 | DMARDs | Los FARME se usan… (singular) |

**SECTION 3. TRANSLATION**

Please, add your sample translation below (between 300-500 words). Bear in mind this should be the best sample of your work!

|  |  |
| --- | --- |
| **Source** | **Target** |
| **INFORMED CONSENT FORM**  **PURPOSE OF THE STUDY**  You are being asked to participate in a study of the investigational drug, AAA. An investigational drug is one that is not approved by the local health authority.  The purpose of this study is to understand how well you respond to AAA, a biologic disease modifying anti-rheumatic drug (DMARD), or another biologic DMARD called etanercept, after it has been determined that you did not respond to the biologic DMARD called adalimumab, during the first 4 months of this study.  AAA, etanercept and adalimumab are all biologic DMARDs; however, each drug is different in how they treat rheumatoid arthritis (RA). This study is intended to show that patients with RA can respond differently to these drugs and provide information to help doctors select which biologic DMARD is best to treat RA patients when they are not doing well with the medication they are currently using. Both adalimumab (BBB®) and etanercept (CCC®) are approved products, and currently marketed in a number of countries, including Europe, Japan, and the United States for the treatment of rheumatoid arthritis.  AAA is a type of drug called an anti-interleukin 6 receptor monoclonal antibody (a type of protein). AAA blocks the activity of interleukin 6 (IL-6) in your body. IL-6 is known to be an important protein that is elevated in patients with RA and is felt to contribute to RA symptoms and joint damage. AAA is an investigational drug that has not been approved for marketing by the health authorities.  **INVESTIGATOR BROCHURE**  Preclinical pharmacology studies demonstrate that AAA is a hypoxia-selective cytotoxic drug when profiled in both human cancer cell line-based in vitro assays and in human tumor xenograft in vivo models.  In an in vitro proliferation assay in H460 cells was conducted at different oxygen concentrations, the cytotoxic activity increased with decreasing oxygen levels.  Across a large panel of 32 human cancer cell lines, AAA demonstrated modest cytotoxicity under normoxia with IC50 values between 40 and 1000 μmol/L.  In contrast, substantially increased cytotoxicity was observed under hypoxic conditions in all 32 cell lines with IC50 values between 0.1 and 90 μmol/L. | **FORMULARIO DE CONSENTIMIENTO INFORMADO**  **OBJETIVO DEL ESTUDIO**  Se le solicita participar en un estudio de fármaco en investigación, AAA. Un fármaco en investigación es aquel que no está aprobado por la autoridad sanitaria local.  El objetivo de este estudio es entender qué tan bien responde a AAA, un fármaco antirreumático modificador de la enfermedad (FARME) u otro FARME biológico llamado etanercept, esto después de que se haya determinado que no respondió al FARME biológico llamado adalimumab, durante los 4 primeros meses del estudio.  AAA, el etanercept y el adalimumab son FARME biológicos, sin embargo, cada uno es distinto en tratar la artritis reumática (AR). Este estudio pretende demostrar que pacientes con AR pueden responder de forma distinta a estos fármacos por lo que puede proveer información que ayude a los médicos a seleccionar el tipo de FARME biológico adecuado para tratar a los pacientes con AR que no responden adecuadamente al medicamento que actualmente utilizan. El adalimumab (BBB®) y el etanercept (CCC®) son productos aprobados para el tratamiento de la artritis reumatoide y actualmente se comercializan en varios países incluyendo Europa, Japón y Estados Unidos.  El AAA es un tipo de fármaco llamado anticuerpo monoclonal contra el receptor de la interleucina 6 (un tipo de proteína). AAA bloquea la actividad de la interleucina 6 (IL-6) en el organismo. IL-6 es conocido como una proteína esencial que está elevada en pacientes con AR y se considera que contribuye a los síntomas de la AR y al daño articular. AAA es un fármaco en investigación que no ha sido aprobado por las autoridades sanitarias para su comercialización.  **FOLLETO DEL INVESTIGADOR**  Los estudios farmacológicos preclínicos demuestran que AAA es un fármaco citotóxico selectivo en hipoxia cuando se perfila tanto en ensayos in vitro basados en líneas celulares de cáncer humano, como en modelos in vivo de xenoinjerto de tumores humanos.  En un ensayo de proliferación in vitro en células H460 se llevó a diferentes concentraciones de oxígeno; la actividad citotóxica aumentó al disminuir los niveles de oxígeno. A través de un gran panel de 32 líneas celulares de cáncer humano AAA demostró una citotoxicidad moderada bajo normoxia con valores de IC50; entre 40 y 1000 μmol/L. Por el contrario, se observó citotoxicidad aumentada considerablemente en condiciones hipóxicas en todas las 32 líneas celulares con valores de IC50 entre 0.1 y 90 μmol/L. |

**SECTION 4. QUESTIONS AND COMMENTS**

We also need to check your capacity to spot potential issues beforehand.

In the table below, please list your questions and comments in relation with this test:

1. Challenging sections from the source text or sections you are unsure of should be copied or inserted into the **Source Text** column.

2. Write your translation in the **Target Text** column.

3. Doubts and comments should be written in English.

|  |  |  |
| --- | --- | --- |
| Source Text | Target Text | Question / Comment  (in English) |
| First of all, this is a formal text so the level of linguistic register and tone are according to it.  a) Etanercept and adalimumab are all biologic DMARDs | El etanercept y el adalimumab son FARME biológicos. | In official documents I found article “el” for etanercept and adalimumab. Besides, the articles before a drug name are very common in Spanish speakers, and it gives a natural vibe. I did not find any result with article “la”, so it does not exist. |
| b) Etanercept and adalimumab are all biologic DMARDs | El etanercept y el adalimumab son FARME biológicos. | I found the article “el” in several articles from specialized foundations. No result with article “la”. |
| c) AAA blocks the activity of interleukin 6. | AAA bloquea la actividad de la interleucina 6. | In official documents I found article “la” for interleucina 6. Besides, the article before a drug name is very common in Spanish speakers, and it gives a natural vibe. I did not find any result for “el interleucina”, so it does not exist. |
| Preclinical pharmacology studies demonstrate that AAA is a hypoxia-selective cytotoxic drug when profiled in both human cancer cell line-based in vitro assays and in human tumor xenograft in vivo models. | Los estudios farmacológicos preclínicos demuestran que AAA es un fármaco citotóxico selectivo en hipoxia cuando se perfila tanto en ensayos in vitro basados en líneas celulares de cáncer humano, como en modelos in vivo de xenoinjerto de tumores humanos. | *It’s a very long sentence without pause so I added before “como”.*  *According to RAE, it’s permitted to add it just in case of long sentence. Check on 1.2.10. Part A:* “la presencia de la coma es más conveniente cuanto más largo es el fragmento anticipado” <https://www.rae.es/dpd/coma> |

**SECTION 5. REFERENCES**

In the table below, please list the reference material you have consulted to carry out this test.

1. Please introduce the **Reference source** (including publisher and full title as appropriate) in the first column.
2. Specify if your reference source is general or specific. If specific, clarify which term or section the reference covers.

|  |  |
| --- | --- |
| Reference Source | General / Specific (Term) |
| 1. Arthritis Foundation in Spanish website call it “el Etanercept”.   <http://espanol.arthritis.org/espanol/tratamientos/medicamentos/medicamentos-por-enfermedad/medicamentos-mrb/>  You can find more than 11 results with “el Etanercept” and if you try with “la Etanercept” there is 0 result.  <https://www.google.com/search?q=el+Etanercept&ei=Gu6pYLCqK7eMwbkP0fiXyAI&oq=el+Etanercept&gs_lcp=Cgdnd3Mtd2l6EAMyCAgAEAcQChAeMgYIABAHEB4yCAgAEAgQBxAeMggIABAIEAcQHjIICAAQCBAHEB4yCAgAEAgQBxAeMggIABAHEAUQHjIGCAAQCBAeMgYIABAIEB4yCAgAEAgQChAeOgcIABBHELADOgQIABBDOgIIAFDR6gFY0_ABYKL1AWgBcAJ4AIABsQGIAbcEkgEDMi4zmAEAoAEBqgEHZ3dzLXdpesgBCMABAQ&sclient=gws-wiz&ved=0ahUKEwiwn7zrjt_wAhU3RjABHVH8BSkQ4dUDCBE&uact=5> | Etanercept = El etanercept |
| 1. Arthritis Foundation in Spanish website call “el adalimumab”.   <http://espanol.arthritis.org/espanol/busqueda/?q=el+adalimumab>+  You can find more than 7 results with “el adalimumab” and if you try with “el adalimumab” there is 0 result.  <https://www.google.com/search?q=el+adalimumab&oq=el+adalimumab&aqs=chrome..69i57.1971j0j9&sourceid=chrome&ie=UTF-8> | Adalimumab = el adalimumab |
| 1. Elsevier, a foundation specialized on rheumatology.   <https://www.elsevier.es/es-revista-seminarios-fundacion-espanola-reumatologia-274-articulo-inhibidor-del-receptor-interleucina-6-el-S1577356611000273> | Interleukin = la interleucina |
| Other Sources I used:  Arthritis Foundation (Spanish)  <http://espanol.arthritis.org/espanol/encuentre-ayuda/ayuda-financiera/recursos-farmacos-fase-experimental/>  National Center for Biotechnology Information  <https://www.ncbi.nlm.nih.gov/>  US Food & Drug Administration  <https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-investigational-drugs>  Diccionario médico  <https://www.cun.es/diccionario-medico/terminos/citotoxicidad> | General |

Thanks!